DPP4 and Alzheimer disease: AD has been proposed as ‘type 3 diabetes’, and the anti-diabetic agents (e.g., dipeptidyl peptidase-4, also known as DPP4) has been proposed as novel therapies for AD (Cheng et al., 2020).